Market access routes for genomic diagnostics (GDx) in England are causing delays and inefficiencies for manufacturers, patients, and the National Health Service (NHS) itself, according to an independent whitepaper commissioned by the British In Vitro Diagnostics Association (BIVDA).
Key Takeaways
-
British market access pathways are unclear and complex for GDx
England’s labyrinthine funding and reimbursement pathways lead to delays in access to tests that, in some therapeutic areas such as...